Table II.
Correlation between HMGA1 expression and clinicopathological parameters.
| Variables | n | HMGA1
|
P-value | ||
|---|---|---|---|---|---|
| − | + | ++ | |||
| Age (years), n (%) | 0.077 | ||||
| <50 | 87 | 37 (42.5) | 44 (50.6) | 6 (6.9) | |
| ≥50 | 72 | 23 (31.9) | 38 (52.8) | 11 (15.3) | |
| Tumor type, n (%) | 0.000 | ||||
| Lobular | 79 | 48 (60.8) | 30 (38.0) | 1 (1.3) | |
| Ductal | 79 | 11 (13.9) | 52 (65.8) | 16 (20.3) | |
| Tumor size, n (%) | 0.814 | ||||
| ≤2 cm | 18 | 6 (33.3) | 12 (66.7) | 0 (0.0) | |
| >2 cm | 141 | 54 (38.3) | 70 (49.6) | 17 (12.1) | |
| Node metastasis, n (%) | 0.208 | ||||
| Negative | 93 | 39 (41.9) | 45 (48.4) | 9 (9.7) | |
| Positive | 66 | 21 (31.8) | 37 (56.1) | 8 (12.1) | |
| Nuclear grade, n (%) | 0.097 | ||||
| 1 | 3 | 0 (0.0) | 2 (66.7) | 1 (33.3) | |
| 2 | 60 | 6 (10.0) | 40 (66.7) | 14 (23.3) | |
| 3 | 12 | 4 (33.3) | 7 (58.3) | 1 (8.3) | |
| ER, n (%) | 0.090 | ||||
| Negative | 104 | 43 (41.3) | 53 (51.0) | 8 (7.7) | |
| Positive | 55 | 17 (30.9) | 29 (52.7) | 9 (16.4) | |
| PR, n (%) | 0.105 | ||||
| Negative | 116 | 46 (39.7) | 62 (53.4) | 8 (6.9) | |
| Positive | 43 | 14 (32.6) | 20 (46.5) | 9 (20.9) | |
| HER2, n (%) | 0.007 | ||||
| Negative | 130 | 54 (41.5) | 66 (50.8) | 10 (7.7) | |
| Positive | 29 | 6 (20.7) | 16 (55.2) | 7 (24.1) | |
Data were from tissue microarrays (BR1921a), which consisted of 159 breast cancer cases, and were histologically interpretable and analyzed for the correlation with clinicopathological parameters. ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; HMGA1, high mobility group A1.